Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Sekar Kathiresan showcases historic monkey data in hunt for a once-and-done gene editing approach to prevent heart attacks

5 years ago

Second death triggers hold on Astellas' $3B gene therapy biotech's lead program, raising fresh concerns about AAV

5 years ago

Novartis-backed Poseida is packing in the cash for its next-gen CAR-T work, adding a $110M venture raise on top of its newly-refiled IPO

5 years ago

Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to leapfrog natural killer competitors

5 years ago

In an unexpected twist, CSL buys worldwide rights to uniQure's PhIII hemophilia B gene therapy in $2B-plus deal

5 years ago

With its campus expanding as gene therapy booms, Aldevron brings in a top exec from a medtech giant to steer the course

5 years ago

What’s it take to raise $700M-plus for a biotech startup? Steve Harr has some thoughts on that

5 years ago

Sarepta expands gene therapy toolkit, bets $72.5M to hitch a ride on Codiak's exosome tech

5 years ago

Cell and gene therapy 2.0 dominates latest round of biotech IPOs in scramble for a $300M-plus Nasdaq windfall

6 years ago

As BioMarin’s lead rival wanes, Pfizer and Sangamo post a promising update for hemophilia A gene therapy

6 years ago

Two Bay Area upstarts out to deliver on cell therapy 2.0 join forces on a quest: pursuing a Holy Grail in oncology R&D

6 years ago

BioMarin spells out a troubling slide in Factor VIII levels for its big blockbuster contender valrox

6 years ago

Eyeing a hot IPO market, 4DMT tops up its cash reserves and preps a leap into the clinic with bespoke gene therapy vectors

6 years ago

LentiGlobin continues to deliver in latest sickle cell update as bluebird outlines path to accelerated approval, despite patient death

6 years ago

Vertex and CRISPR spotlight another important gene editing advance in a march to a hoped-for cure

6 years ago

Juno, WuXi JV in China score $100M in fresh funding as it sets stage for first CAR-T approval

6 years ago

Sanofi sends a pair of gene therapies back to Oxford Biomedica. Are they salvageable?

6 years ago

Lilly, Incyte-allied Chinese drugmaker Innovent bags Roche as partner in deal that could yield billions

6 years ago

Sarepta reveals positive results in limb-girdle gene therapy trial. What does that mean for DMD?

6 years ago

Add ear gene therapy company Akouos to the ever-growing list of IPOs amid Covid-19

6 years ago

Spark touts animal data for a solution to AAV gene therapy's antibody problem

6 years ago

Early survival data boost Ziopharm's 'controlled IL-12' immunotherapy for glioblastoma

6 years ago

Bob Langer-founded cell therapy player loads up $65M to fund Roche-partnered cancer work while expanding into vaccines for infectious diseases

6 years ago

Rare disease drugmaker Ultragenyx builds case for its gene therapy franchise with fresh trial updates

6 years ago

First page Previous page 46 47 484950 51 52 Next page Last page